Healthcare Services

Treatment-Resistant Depression Industry Expansion Forecast Showing Market Size of $2.59 Billion by 2030 at 6.7% CAGR

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Treatment-Resistant Depression Market From 2026 To 2030?

The size of the treatment-resistant depression market has demonstrated robust growth in recent years. This market is projected to expand from $1.87 billion in 2025 to $2 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.9%. Historically, this expansion has been driven by factors such as the increasing prevalence of major depressive disorder, the limited effectiveness of conventional antidepressants, a rise in the diagnosis of refractory depression cases, the growth in psychiatric specialty clinics, and the growing acceptance of advanced mental health therapies.

The market for treatment-resistant depression is anticipated to experience substantial expansion over the coming years, with projections indicating it will reach $2.59 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. This growth during the forecast period is expected to be driven by factors such as increasing investments in precision psychiatry, the growing approval of ketamine and esketamine therapies, the expansion of biomarker-driven treatment selection, a rising demand for long-term depression management solutions, and the increased use of digital therapeutic support tools. Key trends foreseen in this period include the wider adoption of novel rapid-acting antidepressants, an increase in the utilization of neuromodulation therapies, a growing emphasis on personalized psychiatry approaches, the expansion of research into psychedelic-based treatments, and enhanced integration of digital mental health tools.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23546&type=smp

What Major Drivers Are Influencing Demand In The Treatment-Resistant Depression Market?

The increasing incidence of mental health conditions is anticipated to fuel the expansion of the treatment-resistant depression market in the future. Mental disorders encompass a wide spectrum of ailments affecting an individual’s cognitive, emotional, and behavioral functioning, frequently leading to considerable suffering and functional difficulties in daily life. The widespread occurrence of mental disorders stems from various factors, including genetic predisposition, as inherited genetic differences can alter brain chemistry and heighten vulnerability to conditions like depression, anxiety, and schizophrenia. Treatment-resistant depression (TRD) offers assistance to individuals with mental disorders by promoting tailored and sophisticated treatment options when conventional therapies prove ineffective, thereby enhancing their prospects for recovery and overall well-being. For example, data from November 2023, published by the American Psychological Association (APA), a US-based scientific and professional organization, indicated that in 2023, adults aged 18 to 34 had the highest reported incidence of mental illnesses at 50%, whereas those aged 35 to 44 showed the most significant rise in diagnoses, with 45% stating they had a mental illness. Consequently, the substantial occurrence of mental disorders is a key factor propelling the expansion of the treatment-resistant depression market.

Which Segments Are Included In The Analysis Of The Treatment-Resistant Depression Market?

The treatment-resistant depression market covered in this report is segmented –

1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIs), Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Psychedelics

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram

2) By Monoamine Oxidase Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline

3) By Tricyclic Antidepressants (TCAs): Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Doxepin

4) By Psychedelics: Ketamine, Esketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA)

Which Market Trends Are Creating New Opportunities In The Treatment-Resistant Depression Market?

Leading companies in the treatment-resistant depression market are concentrating on developing innovative therapies such as monotherapy to address unmet patient needs, improve efficacy, and reduce side effects. Monotherapy involves the use of a single treatment or medication to manage a condition, rather than combining it with others. It assists in treating treatment-resistant depression by offering a singular, focused approach that may be more effective for patients who haven’t responded to multiple medications. For instance, in January 2025, Johnson & Johnson Services Inc., a US-based pharmaceutical, biotechnology, and medical technology company, announced U.S. Food and Drug Administration (FDA), a US-based government regulatory body, approval for SPRAVATO (esketamine) nasal spray, a fast-acting treatment for adults with treatment-resistant depression (TRD). SPRAVATO is administered in conjunction with an oral antidepressant when patients have not responded adequately to at least two other antidepressant therapies. The drug’s rapid effects tackle the limitations of traditional antidepressants, which often require weeks to show results. As a derivative of ketamine, esketamine operates by targeting the brain’s NMDA receptors, potentially enhancing mood within hours. This approval signaled a significant advancement in the field of mental health treatment.

Which Key Industry Participants Are Active In The Treatment-Resistant Depression Market?

Major companies operating in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience

Read the full treatment-resistant depression market report here:

https://www.thebusinessresearchcompany.com/report/treatment-resistant-depression-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Treatment-Resistant Depression Market?

North America was the largest region in the treatment-resistant depression market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the treatment-resistant depression market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Treatment-Resistant Depression Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23546&type=smp

Browse Through More Reports Similar to the Global Treatment-Resistant Depression Market 2026, By The Business Research Company

Major Depressive Disorder Global Market Report

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Music Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Behavioral Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/behavioral-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795